Isosporiasis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
|||
| Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
[[Trimethoprim-sulfamethoxazole]] is the drug of choice. | [[Trimethoprim-sulfamethoxazole]] is the drug of choice. | ||
==Medical Therapy== | |||
===Antimicrobial Regimen=== | |||
:* 1. '''Cystoisospora belli treatment'''<ref>{{cite web | title = CDC - Cystoisosporiasis | url = http://www.cdc.gov/parasites/cystoisospora/health_professionals/index.html }}</ref> | |||
::* 1.1 '''Immunocompetent hosts''' | |||
:::* In the immunocompetent hosts, symptoms of Cystoisospora infection are usually self-limited. | |||
:::* Antimicrobial therapy to immunocompetent patients may be considered if symptoms do not start to resolve spontaneously after 5 to 7 days (depending upon severity) | |||
:::* Prefered regimen: [[Trimethoprim-sulfamethoxazole]] 160 mg/800 mg PO bid for 7-10 days | |||
:::* Alternative regimen (1) (for patients who are allergic to or intolerant of TMP-SMX): [[Pyrimethamine]] 50-75 mg/day PO qd or divided in 2 equal doses {{and}} [[Leucovorin]] 10–25 mg PO qd | |||
:::* Alternative regimen (2): [[Ciprofloxacin]] 500 mg PO bid for 7 days (second-line alternative) | |||
::::* 1.1.1 '''In pregnancy''' | |||
:::::* TMP-SMX should be avoided near-term because of the potential for hyperbilirubinemia and kernicterus in the newborn. | |||
:::::* Ciprofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. | |||
::::* 1.1.2 '''During lactation''' | |||
:::::* TMP-SMX generally should be avoided by women when nursing infants who are premature, jaundiced, ill, or stressed, or who have glucose-6-phosphate dehydrogenase deficiency. | |||
:::::* The American Academy of Pediatrics classifies Ciprofloxacin as usually compatible with breastfeeding, whereas the World Health Organization recommends avoiding Ciprofloxacin while breastfeeding and CDC recommends Ciprofloxacin should be used during lactation only if the potential benefit justifies the potential risk to the fetus. | |||
::::* 1.1.3 '''In pediatric patients''' | |||
:::::* The use of TMP-SMX in children less than 2 months of age generally is not recommended. | |||
:::::* Available evidence is conflicting regarding the potential for growth defects and arthropathies in exposed children. Use of Ciprofloxacin in children requires assessment of potential risks and benefits. | |||
::* 1.2 '''Immunocompromised hosts''' | |||
:::* Preferred regimen (1): [[Trimethoprim-sulfamethoxazole]] 160 mg/800 mg PO/IV qid for 10 days | |||
:::* Preferred regimen (2): [[Trimethoprim-sulfamethoxazole]] 160 mg/800 mg PO/IV bid for 7-10 days | |||
:::* Note (1): One approach is to start with TMP-SMX (160 mg/800 mg) bid regimen first, and increase daily dose and/or duration (up to 3–4 weeks) if symptoms worsen or persist. | |||
:::* Note (2): IV therapy is recommended for patients with potential or documented malabsorption. | |||
:::* Alternative regimen (1): [[Pyrimethamine]] 50–75 mg PO qd {{and}} [[Leucovorin]] 10–25 mg PO qd | |||
:::* Alternative regimen (2): [[Ciprofloxacin]] 500 mg PO bid for 7 days | |||
:* 2. '''Cystoisospora belli prophylaxis'''<ref>{{cite web | title = Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents | url = https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf }}</ref> | |||
::* 2.1 '''Primary prophylaxis''' | |||
:::* Insufficient evidence is available to support a general recommendation for primary prophylaxis for Cystoisosporiasis per se, especially for U.S. travelers in isoporiasis-endemic areas. | |||
::* 2.2 '''Secondary prophylaxis (preventing recurrence in patients with CD4 count < 200 cells/mm<sup>3</sup>)''' | |||
:::* Prefered regimen: [[Trimethoprim-sulfamethoxazole]] 160 mg/800 mg PO 3 times weekly | |||
:::* Alternative regimen (1): [[Trimethoprim-sulfamethoxazole]] 160 mg/800 mg PO qd | |||
:::* Alternative regimen (2): [[Trimethoprim-sulfamethoxazole]] 320 mg/1600 mg PO 3 times weekly | |||
:::* Alternative regimen (3): [[Pyrimethamine]] 25 mg PO qd {{and}} [[Leucovorin]] 5–10 mg PO qd | |||
:::* Alternative regimen (4): [[Ciprofloxacin]] 500 mg PO 3 times weekly (second-line alternative) | |||
:::* Note (1): Criteria for discontinuation of chronic maintenance therapy: sustained increase in CD4 count > 200 cells/mm<sup>3</sup> for > 6 months in response to ART and without evidence of active Cystoisospora belli infection | |||
:::* Note (2): Because of concerns about possible teratogenicity associated with first-trimester drug exposure, clinicians may withhold secondary prophylaxis during the first trimester and treat only symptomatic infection. | |||
==References== | ==References== | ||
| Line 13: | Line 51: | ||
{{Protozoal diseases}} | {{Protozoal diseases}} | ||
[[Category:Infectious Disease Project]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Parasitic diseases]] | [[Category:Parasitic diseases]] | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Revision as of 18:38, 16 July 2015
|
Isosporiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Isosporiasis medical therapy On the Web |
|
American Roentgen Ray Society Images of Isosporiasis medical therapy |
|
Risk calculators and risk factors for Isosporiasis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Trimethoprim-sulfamethoxazole is the drug of choice.
Medical Therapy
Antimicrobial Regimen
- 1. Cystoisospora belli treatment[1]
- 1.1 Immunocompetent hosts
- In the immunocompetent hosts, symptoms of Cystoisospora infection are usually self-limited.
- Antimicrobial therapy to immunocompetent patients may be considered if symptoms do not start to resolve spontaneously after 5 to 7 days (depending upon severity)
- Prefered regimen: Trimethoprim-sulfamethoxazole 160 mg/800 mg PO bid for 7-10 days
- Alternative regimen (1) (for patients who are allergic to or intolerant of TMP-SMX): Pyrimethamine 50-75 mg/day PO qd or divided in 2 equal doses AND Leucovorin 10–25 mg PO qd
- Alternative regimen (2): Ciprofloxacin 500 mg PO bid for 7 days (second-line alternative)
- 1.1.1 In pregnancy
- TMP-SMX should be avoided near-term because of the potential for hyperbilirubinemia and kernicterus in the newborn.
- Ciprofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
- 1.1.2 During lactation
- TMP-SMX generally should be avoided by women when nursing infants who are premature, jaundiced, ill, or stressed, or who have glucose-6-phosphate dehydrogenase deficiency.
- The American Academy of Pediatrics classifies Ciprofloxacin as usually compatible with breastfeeding, whereas the World Health Organization recommends avoiding Ciprofloxacin while breastfeeding and CDC recommends Ciprofloxacin should be used during lactation only if the potential benefit justifies the potential risk to the fetus.
- 1.1.3 In pediatric patients
- The use of TMP-SMX in children less than 2 months of age generally is not recommended.
- Available evidence is conflicting regarding the potential for growth defects and arthropathies in exposed children. Use of Ciprofloxacin in children requires assessment of potential risks and benefits.
- 1.2 Immunocompromised hosts
- Preferred regimen (1): Trimethoprim-sulfamethoxazole 160 mg/800 mg PO/IV qid for 10 days
- Preferred regimen (2): Trimethoprim-sulfamethoxazole 160 mg/800 mg PO/IV bid for 7-10 days
- Note (1): One approach is to start with TMP-SMX (160 mg/800 mg) bid regimen first, and increase daily dose and/or duration (up to 3–4 weeks) if symptoms worsen or persist.
- Note (2): IV therapy is recommended for patients with potential or documented malabsorption.
- Alternative regimen (1): Pyrimethamine 50–75 mg PO qd AND Leucovorin 10–25 mg PO qd
- Alternative regimen (2): Ciprofloxacin 500 mg PO bid for 7 days
- 2. Cystoisospora belli prophylaxis[2]
- 2.1 Primary prophylaxis
- Insufficient evidence is available to support a general recommendation for primary prophylaxis for Cystoisosporiasis per se, especially for U.S. travelers in isoporiasis-endemic areas.
- 2.2 Secondary prophylaxis (preventing recurrence in patients with CD4 count < 200 cells/mm3)
- Prefered regimen: Trimethoprim-sulfamethoxazole 160 mg/800 mg PO 3 times weekly
- Alternative regimen (1): Trimethoprim-sulfamethoxazole 160 mg/800 mg PO qd
- Alternative regimen (2): Trimethoprim-sulfamethoxazole 320 mg/1600 mg PO 3 times weekly
- Alternative regimen (3): Pyrimethamine 25 mg PO qd AND Leucovorin 5–10 mg PO qd
- Alternative regimen (4): Ciprofloxacin 500 mg PO 3 times weekly (second-line alternative)
- Note (1): Criteria for discontinuation of chronic maintenance therapy: sustained increase in CD4 count > 200 cells/mm3 for > 6 months in response to ART and without evidence of active Cystoisospora belli infection
- Note (2): Because of concerns about possible teratogenicity associated with first-trimester drug exposure, clinicians may withhold secondary prophylaxis during the first trimester and treat only symptomatic infection.